"Surgery lowers risks of death, heart disease, kidney failure, and eye damage more than GLP-1 medicines. Date:Source:Cleveland ClinicSummary:Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications. Experts say surgery continues to offer survival advantages even in the age of potent obesity drugs. Share:"
"A major study from Cleveland Clinic found that people with both obesity and type 2 diabetes who had weight-loss surgery lived longer and experienced fewer serious health issues than those who used GLP-1 receptor agonist medications alone. These drugs, which mimic a natural hormone that helps regulate blood sugar and appetite, are commonly prescribed for diabetes and weight management. They include medications such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and tirzepatide (Mounjaro, Zepbound)."
For people with obesity and type 2 diabetes, bariatric/metabolic surgery produced greater and more durable weight loss, superior glycemic control, and reduced need for diabetes and cardiovascular medications compared with treatment using GLP-1 receptor agonists alone. Surgery was associated with lower risks of death, heart disease, kidney failure, and eye damage over a decade. GLP-1 medications commonly prescribed for diabetes and weight management include semaglutide, liraglutide, dulaglutide, exenatide, and tirzepatide. The metabolic benefits of surgery persisted long-term and extended beyond mere weight loss to improved survival and organ protection.
Read at ScienceDaily
Unable to calculate read time
Collection
[
|
...
]